Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCentene Ambetter Formulary Coverage & PA | OpenPay…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentCentenePolicy AMB25-AHS-C-00023-FL

    Ambetter Formulary (Prescription Drug List) — Coverage Criteria

    Customize your policy alerts

    Sign up for Centene Policy AMB25-AHS-C-00023-FL alerts

    Get alerted when Policy AMB25-AHS-C-00023-FL changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines the Ambetter prescription drug formulary, tiers, coverage guidance, prior authorization and limits for covered drugs under the Centene/Ambetter benefit; affects providers prescribing and dispensing prescription and specialty drugs to Ambetter members.

    Policy Summary
    PayerCentene
    PolicyAmbetter Formulary (Prescription Drug List) — Coverage Criteria
    Policy CodePolicy AMB25-AHS-C-00023-FL
    Change TypeNo material changes
    Effective DateJan 1, 2026
    Next Review Date
    Key ActionProviders must submit a completed Prior Authorization form with supporting documentation for drugs noted with PA; urgent requests are responded to within 24 hours and non-urgent within 72 hours.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Jan 2026Formulary edition
    7-dayOpioid new-start limit
    PA & QLUtilization management
    24/72hPA response times
    biologic/specialtySpecialty categories

    Formulary Coverage Criteria and Limits

    General Coverage

    Covered when ALL of the following are met:

    Formulary coverage basics: Drugs listed on the Ambetter Formulary are covered under the prescription drug benefit subject to plan design, formulary tier, and any listed restrictions (QL, AL, PA, ST). Generics are preferred when available; preferred brand drugs appear on Tier 2.

    Not all dosage forms or strengths may be covered; specific plan designs may impose additional limitations.

    Opioid Supply Limits

    Covered when ALL of the following are met:

    Opioid new-start supply limits: New opioid starts are limited to a 7‑day supply. Allow up to two 7‑day fills during any 28‑day period and up to a total of 28 non‑consecutive days' supply in any 90‑day period. Providers may submit prior authorization requests for fills exceeding these limits.7-day limit; max 28 days per 90
    Policy Summary
    PayerCentene
    PolicyAmbetter Formulary (Prescription Drug List) — Coverage Criteria
    Policy CodePolicy AMB25-AHS-C-00023-FL
    Change TypeNo material changes
    Effective DateJan 1, 2026
    Next Review Date
    Key ActionProviders must submit a completed Prior Authorization form with supporting documentation for drugs noted with PA; urgent requests are responded to within 24 hours and non-urgent within 72 hours.
    SourceLink
    On This Page
    Formulary Coverage Criteria and LimitsFormulary Annotation Codes and Key LimitsPrior Authorization, Step Therapy, and Documentation RequirementsInitial Prescribing Limits and New-Start RulesContinuation Beyond Initial SupplyStep Therapy Indicators and ExamplesQuantity Limits (QL) — Examples and Product-Specific ValuesAdditional Quantity Limits and ExamplesRemaining Quantity Limit ExamplesSpecialty Pharmacy and Dispensing RequirementsBiosimilar Listings and HandlingFormulary Terms and AbbreviationsBackground and ScopePolicy Revision History

    Limits apply cumulatively to all opioid medications filled.

    Formulary administrative coverage conditions

    Coverage and dispensing restrictions apply as indicated for each product line when ALL listed administrative conditions are met

    Formulary administrative conditions: Product is subject to the listed tier, quantity limits (QL), and prior authorization (PA) where indicated; new‑start supply limits apply for many products.

    Clinical medical necessity criteria are not included in this extract

    Formulary tier and authorization indicators

    Coverage stance is indicated by Tier and presence of PA/QL flags for individual products.

    Tiered coverage: Products are assigned formulary tiers (examples: Tier 0, 1A, 1B, 2, 3, 4). Tier determines coverage category and member cost sharing.

    See individual product entries for exact tier assignments.

    Utilization management flags: Presence of 'PA' indicates prior authorization is required; 'QL' entries specify quantity limits; 'ST' indicates step therapy requirements.per product

    Refer to product rows for QL/PA/ST details.

    Formulary tiering and utilization management overview (excerpt)

    Coverage and utilization management vary by drug; the following patterns are present in this excerpt.

    Tiered coverage: Drugs are assigned tiers (e.g., 1A, 1B, 2, 3, 4) which affect coverage and cost sharing.

    Examples and exact tiers are listed on product rows.

    PA/SP requirements: Many specialty and higher‑tier drugs require prior authorization (PA) or specialty prior authorization (SP).

    Examples in the formulary include multiple tier 4 specialty agents marked PA or SP.

    Quantity Limits: Several products include explicit quantity limits (QL) by strength/formulation that constrain dispensing frequency and amount.

    QL values are provided per product line (see entries).

    Contraceptives coverage entries

    Coverage for contraceptive products is provided as listed; follow tier, QL and fill limits shown per product.

    Contraceptives listed: Combination and progestin contraceptives (oral, implant, injectable, IUD, transdermal, emergency) are included with tier assignments; some entries include quantity limits or package/fill limits.

    Examples include levonorgestrel‑ethinyl estradiol 91‑day, NEXPLANON, PARAGARD, KYLEENA, LILETTA, TWIRLA with QL or fill interval annotations.

    Glucocorticosteroids and systemic steroid products

    Systemic and injectable corticosteroids are covered per product lines and may include fill limits or age annotations.

    Steroid products: Systemic and injectable glucocorticosteroids (e.g., SOLU‑CORTEF, SOLU‑MEDROL, DEPO‑MEDROL, dexamethasone, methylprednisolone) are listed with tiers and some fill/age limits (e.g., SOLU‑CORTEF 500/1000 mg: max fills per 30 days; AL annotations on certain strengths).

    See individual product entries for exact ILimits/Q L/AL values.

    Acne and topical dermatologic agents

    Topical and systemic acne therapies are covered when product‑specific administrative rules are met.

    Topical acne agents and isotretinoin: Benzoyl peroxide products, clindamycin topical formulations, combination gels/foams, tretinoin products, and oral isotretinoin are listed. Many topical agents include age limits (AL, commonly at least 12 years) and QL limits; isotretinoin requires PA and has QL(60 GM per 30 days).

    Some combination topical products also require PA or have ST/AL flags.

    Antifungals and other topical agents

    Topical antifungal agents are covered when dispensing adheres to the listed limits and tiers.

    Topical antifungals: Ciclopirox and clotrimazole topical formulations and combination steroid/antifungal products are present with quantity limits and fill‑interval restrictions (e.g., ciclopirox cream QL(90 GM per 1 max fill(s) per 30); clotrimazole cream QL(4.5 GM daily) with 1 max fill per 180 days).

    Follow per‑product QL and fill limits at dispensing.

    Formulary coverage with product-specific limits and authorization

    Each product row defines coverage stance, tier, quantity limits, and any utilization management flags that govern dispensing.

    Per‑product coverage rules: Formulary entries include the coverage tier, QL (quantity limits), max fill/interval limits, and PA or ST flags where applicable. Pharmacy claims and authorizations must follow the per‑product ILimits values shown in the formulary rows.per entry

    Interpret individual product rows for precise operational limits and authorization requirements.

    Formulary entries in this document may appear for informational purposes but may not be covered for every member. Specific prescription benefit plan designs may not cover certain products or categories regardless of their appearance in this document; always check the member's benefit plan and cost‑sharing information for coverage limitations and applicable member responsibility.

    This extract does not include clinical exclusion lists. The formulary rows shown are administrative in nature (tier, QL, PA, AL, ST) and no explicit clinical exclusion criteria are provided within this extract.

    Within the chunks reviewed there are no statements that designate products as categorically excluded; entries are presented as formulary listings with tier and utilization management annotations and no explicit exclusions are listed in these chunks.

    The contraceptive segment of the formulary enumerates many products (oral, implant, IUD, transdermal, emergency) with tier and quantity annotations but contains no explicit non‑covered or exclusionary statements in this contraceptive segment.

    For the topical dermatologic and related product listings reviewed, entries specify tiers, quantity limits and age limits where applicable; this segment does not include statements declaring products as excluded and no explicit exclusions are listed in this segment of the formulary.

    Digestive enzyme products in the extract (examples: CREON, ZENPEP) are annotated to indicate administrative oversight for non‑standard uses. Non‑FDA approved uses require Prior Authorization as noted for these digestive enzyme preparations.

    The portions of the formulary provided focus on tiering and administrative controls and do not include language that labels therapies as 'not medically necessary.' The excerpt does not list 'not medically necessary' statements for the agents shown.

    Review of the opioid antagonist and related entries shows utilization management flags (PA, QL) but no explicit 'not medically necessary' statements are present in these chunks of the extract.

    Topical and dermatologic entries include QL and AL notations and PA where indicated, but the extract contains no explicit 'not medically necessary' statements in this segment.

    Formulary Annotation Codes and Key Limits

    Formulary restriction/abbreviation codesmixed
    QLQuantity Limit
    ALAge Limit
    PAPrior Authorization
    STStep Therapy
    NFNon-formulary
    SPSpecialty Drug
    Quantity limit notations appearing in formulary entriesmixed
    QL(4 EA daily)Quantity limit example shown for unspecified opioid product
    QL(0.146 ML daily)Quantity limit for ENBREL MINI/SOLN (listed in document)
    Authorization/administrative codes and tieringmixed
    PAPrior authorization required
    Tier = 1BFormulary tier designation as shown
    AL(At least 45 yrs old Up to 79 yrs old)Age limitation example applied to OTEZLA entries
    Anticoagulant products (sample entries)mixed
    ELIQUIS TABSapixaban tablets listed with QL(2 EA daily) in some entries
    XARELTO TABS 10 MG, 20 MGrivaroxaban tablets with QL(1 EA daily) or tier assignments
    rivaroxaban SUSR 1 MG/MLrivaroxaban suspension with QL(900 ML per 30)
    Anxiolytics / benzodiazepinesmixed
    alprazolam TABS 0.25/0.5/1 MGbenzodiazepine with QL(4 EA daily) and tier assignments
    lorazepam TABS 1 MGlorazepam with QL(4 EA daily)
    Respiratory inhalantsmixed
    albuterol sulfate AERS/NEBU/SYRP/TABSmultiple albuterol formulations with tiers and limits
    budesonide (inhalation) SUSPinhaled steroid with C; QL(4 ML daily); PA
    Androgen / testosterone formulationsmixed
    testosterone cypionate SOLN IM 200 MG/MLlisted with tier/category mapping
    testosterone enanthate SOLN IMlisted with tier/category mapping
    Heparins / Low-molecular-weight heparinsmixed
    enoxaparin sodium SOLN IJ 300 MG/3MLenoxaparin with ILimits = QL(6 ML daily)
    enoxaparin sodium SOSY 60 MG/0.6MLenoxaparin SOSY with ILimits = 30 Day(s)| Idaily; PA
    Formulary annotationsmixed
    RXIOTCOTC/RX designation as presented in formulary (appears as RXIOTC)
    Selected oncology drug entriesmixed
    TAGRISSO 40 MGTAGRISSO 40 MG — QL(2 EA daily); PA
    TAGRISSO 80 MGTAGRISSO 80 MG — PA
    GILOTRIFGILOTRIF — QL(1 EA daily); SP; PA
    Additional oncology entriesmixed
    VERZENIOVERZENIO — QL(2 EA daily); PA
    VITRAKVI CAPSVITRAKVI CAPS — SP; PA
    Antipsychotic / psychiatric agentsmixed
    FANAPTFANAPT — QL(2 EA daily); PA
    paliperidonepaliperidone — Tier 1B
    No billing codes in this segmentmixed
    No codes listed
    inv-33: Quantity and age thresholds — examples of QL/AL formats
    Example quantity limits (stimulants)QL(1 EA daily); QL(2 EA daily); QL(6 EA daily); QL(280 ML per 56 days)
    Age threshold exampleAL(At least 6 yrs old)
    New-start notationNew starts limited to 7 day supply (appears on multiple products)
    inv-34: Package / time window limits — package(s) per 180 days examples
    Package / 180‑day windowpackage(s) per 180 day(s) retail; package(s) per 180 day(s) mail
    Max fill per 180 days (example)1 max fill(s) per 180 day(s) retail
    Limit notation usageApplied to biosimilars and other multi‑package products (e.g., ADALIMUMAB variants)
    inv-35: ACTEMRA quantity limit example
    ACTEMRA ACTPEN quantity limitQL(3.6 mL per 28 day(s) retail; 4 mL per 28 day(s) mail)
    ACTEMRA specialty flagsTier = 4; ILimits may include SP; PA on some presentations
    Documentation notePA and QL values must be provided on PA/claims as indicated
    inv-36: Adalimumab QL example
    Adalimumab common QLQL(0.143 EA daily)
    Adalimumab package limitpackage(s) per 180 day(s) retail/mail; 1 max fill(s) per 180 day(s)
    PA requirementPA noted on multiple adalimumab biosimilar entries
    inv-37: Age limit for OTEZLA entries
    OTEZLA age limitsAL(At least 45 yrs old Up to 79 yrs old)
    OTEZLA QL and packageQL(2 EA daily); 1 package(s) per 180 day(s) retail for TBPK
    OTEZLA PA flagPA indicated on OTEZLA entries
    inv-38: Quantity limits examples — verbatim QL values
    Verbatim QL examples (selected)QL(2 GM daily); QL(4 EA daily); QL(900 ML per 30)
    Additional verbatim formatsQL(8 EA daily); QL(60 EA per fill); QL(0.143 ML daily)
    InterpretationQL(...) denotes maximum permitted quantity over stated period (per day/per fill/per X days)
    inv-39: XARELTO SUSR QL
    XARELTO SUSR QLQL(900 ML per 30 day(s))
    XARELTO tabs QL examplesXARELTO TABS 10/20 MG QL(1 EA daily); 15 MG QL(2 EA daily)
    Specialty/pack notesStarter packs and SUSR forms have distinct QL and max‑fill annotations
    inv-40: enoxaparin SOSY 60 MG QL
    enoxaparin SOSY 60 MG QLILimits appear as 30 Day(s)| Idaily; (interpreted as QL/interval with PA)
    enoxaparin SOLN IJ 300 MG/3MLQL(6 ML daily)
    enoxaparin 30 MG SOSYQL(0.6 ML daily); some presentations flagged SP; PA

    Prior Authorization, Step Therapy, and Documentation Requirements

    Prior Authorization

    Submit PA form and documentation for PA‑marked/non‑formulary drugs

    Providers must complete and submit the Ambetter Prior Authorization (PA) form and include all required supporting documentation when requesting coverage for non‑formulary drugs or any product noted with 'PA' on the formulary. Urgent PA requests will be answered within 24 hours and non‑urgent requests within 72 hours (unless state law requires faster response); a denied PA notice will state the specific reasons for disapproval or identify missing information needed to complete the request.

    • Complete Ambetter PA form and supply all requested clinical information.
    • Expect urgent PA response within 24 hours and non‑urgent within 72 hours.
    • Denial notices will include reasons for denial or identify missing material information.
    Prior Authorization

    Adalimumab biosimilars require PA and must meet QL/packaging limits

    Multiple adalimumab presentations and biosimilars are subject to prior authorization and specific quantity limits (e.g., QL(0.143 EA daily); package/180‑day package limits). Providers must request PA and document dosing/indication consistent with the formulary entry when prescribing these products.

    • Adalimumab variants (including ADALIMUMAB‑AATY/ADAZ/ADBM/RYVK, HUMIRA) list ILimits = QL(0.143 EA daily) and PA; some forms show package(s) per 180 day(s) limits.
    • Include documentation of intended dosing and any prior biologic therapy as part of the PA request.
    Prior Authorization

    Obtain PA and document dosing for specialty/inhaled/infused agents

    High‑cost specialty agents (examples: ARIKAYCE, ACTEMRA) are managed with prior authorization and product‑specific quantity limits; providers must obtain PA and document clinical necessity and dosing per the formulary limits.

    • ARIKAYCE entries indicate ILimits = PA (Tier 4) — obtain PA prior to dispensing.
    • ACTEMRA ACTPEN/ACTEMRA SOLN have QL entries (e.g., QL(3.6 mL per 28 day(s) retail; 4 mL per 28 day(s) mail) and some presentations list PA or SP; include dose/frequency in PA documentation.
    Prior Authorization

    Prior authorization required for listed opioid and select analgesic products

    Several opioid and selected non‑opioid products are designated 'PA' on their formulary lines; providers must secure prior authorization before coverage will be approved for these listed products.

    • Opioid entries frequently show 'New starts limited to 7 day supply' and PA for certain formulations — confirm PA before dispensing beyond allowed initial supply.
    • Examples include hydrocodone, hydromorphone, and combination analgesic products that list PA alongside QL or new‑start restrictions.
    Prior Authorization

    Obtain PA for products with ILimits = PA shown on formulary rows

    Some formulary entries explicitly show ILimits = PA (examples include albendazole and certain enoxaparin presentations). When ILimits = PA appears on the product line, providers must obtain prior authorization prior to coverage adjudication.

    • Albendazole is listed with ILimits = PA and requires PA for coverage.
    • Enoxaparin SOSY 60 MG/0.6ML entries show ILimits = PA — obtain PA where indicated.
    Denial Risk

    Do not dispense PA‑marked drugs without approved prior authorization

    Multiple products in the formulary are marked 'PA' — providers must submit prior authorization for these items to be considered for coverage. Do not dispense expecting automatic coverage when a PA flag is present.

    • Examples of PA‑marked items include SPRAVATO, certain anticonvulsants, and others shown in the formulary.
    • Claims for PA‑flagged drugs may be denied if no approved prior authorization is on file.
    Prior Authorization

    Request PA and include dosing/indication for PA‑listed diabetes/GLP‑1 agents

    Selected branded and specialty diabetes agents (e.g., OZEMPIC, TRULICITY and combination products) list PA and QL; providers must request PA and document the indication and dosing consistent with the formulary requirements.

    • OZEMPIC entries show ILimits = QL and PA (e.g., QL(0.108 ML daily); PA).
    • TRULICITY is listed with QL(0.143 ML daily) and PA for some presentations — include clinical rationale with PA request.
    Prior Authorization

    Obtain PA for products explicitly designated PA in product lines

    Certain formulary rows are designated 'PA' and require prior authorization before coverage (examples shown throughout product lists); providers must obtain PA per the formulary entry to avoid claim denial.

    • Review the product line for ILimits = PA and submit PA accordingly.
    • Examples span anti‑infectives, antifungals, and other therapeutic classes where PA is indicated.
    Prior Authorization

    PA required for specialty/tier‑4 oncology and biologic agents

    Many specialty and tier‑4 agents — including selected oncology and biologic therapies (examples: LENVIMA, MVASI, ZIRABEV) — require prior authorization and may be routed through specialty pharmacy; providers must submit PA and follow specialty routing when indicated.

    • LENVIMA lists ILimits = QL and PA; MVASI and ZIRABEV are Tier 4 with ILimits = PA.
    • Specialty (SP) designation may require dispensing via a participating specialty pharmacy network.
    Documentation Required

    Follow XIFAXAN age and QL rules and obtain PA when required

    XIFAXAN 200 mg is listed with quantity limits (e.g., QL(3 EA daily; 9 EA per 3 day(s) retail)) and an age‑related PA note (At least 12 yrs old); providers must ensure age and QL requirements are met and obtain PA where noted.

    • Confirm member meets age requirement (At least 12 yrs old) where specified.
    • Adhere to QL (3 EA daily; 9 EA per 3 days retail) or request PA for exceptions.
    Prior Authorization

    Submit PA (and SP routing if shown) for oncology/specialty agents

    Selected oncology and specialty drugs are annotated with 'PA' or 'SP; PA' (examples: TAGRISSO, GILOTRIF, VECTIBIX) — providers must submit prior authorization and any specialty‑pharmacy routing documentation required for coverage.

    • TAGRISSO 40 mg notes QL(2 EA daily) and PA; many oncology entries list SP; PA.
    • Include clinical indication, prior therapies, and dosing in PA requests for antineoplastics.
    Prior Authorization

    Obtain PA and follow ST where entries are flagged PA/ST

    Certain products in this segment are flagged PA or ST (e.g., FANAPT marked PA; STRIBILD marked PA); providers must obtain prior authorization (and follow step therapy when ST is present) before coverage is approved.

    • FANAPT lists QL and PA; STRIBILD lists QL and PA.
    • If ST is present, evidence of required prior therapy may be necessary with the PA.
    Billing Rule

    Arrange PA and specialty‑pharmacy fulfillment when SP or SP; PA flagged

    Some drugs/formulations require both prior authorization and specialty pharmacy fulfillment (SP; PA). When a product is annotated with SP or 'SP; PA', providers must obtain PA and arrange dispensing through an appropriate specialty pharmacy network.

    • Examples include certain verapamil CP24 formulations, UPTRAVI, and ADEMPAS which list PA and/or SP.
    • Confirm participating specialty pharmacy and include SP routing details with the PA submission.
    Prior Authorization

    Obtain PA and document age/dosing for isotretinoin and PA‑marked topical acne products

    Isotretinoin (10–40 mg) and multiple topical combination acne products are marked 'PA' and have age and quantity restrictions (e.g., isotretinoin QL(60 GM per 30 day(s))). Providers must request PA and document age, indication, and dosing.

    • Isotretinoin requires PA and has QL(60 GM per 30 day(s)) noted.
    • Topical benzoyl peroxide and combination products may include AL and PA — include age and clinical justification in PA.
    Prior Authorization

    Prior authorization required for listed topical antifungals and combinations

    Multiple topical products and strengths (examples: luliconazole, ketoconazole topical) include 'PA' in their formulary lines; providers must obtain prior authorization per the entry prior to coverage.

    • Luliconazole and ketoconazole topical entries indicate ILimits = PA; follow PA procedures before dispensing.
    • Confirm any associated QL or max‑fill restrictions in the formulary row.
    Prior Authorization

    Request PA and follow max‑fill/interval rules for specialty/bone agents

    Certain specialty/bone agents (e.g., EUCRISA, PROLIA, pamidronate, risedronate, teriparatide) include PA or SP flags and max‑fill/interval limits. Providers must secure PA and adhere to max‑fill per 180‑day or other interval restrictions when noted.

    • PROLIA entries show max fill(s) per 180 day(s) — obtain PA and observe fill interval limits.
    • Pamidronate disodium SOLN and pamidronate entries are SP; PA — arrange specialty dispensing and PA as required.
    Prior Authorization

    PA required for non‑FDA uses of digestive enzyme preparations

    Digestive enzyme products (e.g., CREON, ZENPEP) indicate that non‑FDA approved uses require prior authorization. Providers seeking coverage for off‑label enzyme use must submit PA documenting the non‑FDA indication and clinical rationale.

    • CREON and ZENPEP entries state 'Non‑FDA approved uses require Prior Authorization'.
    • Include supporting clinical documentation when requesting PA for non‑FDA uses.
    Prior Authorization

    Obtain PA for the multiple PA‑noted products or classes to avoid denial

    Many listed products and classes (examples: pamidronate disodium, ACTHAR GEL, tolvaptan, octreotide, various biologics) have 'PA' noted; providers must obtain prior authorization where indicated to prevent claim denial.

    • ACTHAR GEL and ACTHAR GEL PEN list ILimits = PA — submit PA prior to dispensing.
    • Tolvaptan and octreotide entries indicate QL and PA — include dosing and indication with PA.
    Step Therapy

    Follow step therapy (ST) when formulary entries indicate ST

    Step therapy (ST) applies where indicated on the formulary; when a product row includes 'ST', providers must document that required preferred alternatives were tried (or submit justification) before coverage of the listed product will be approved.

    • Lisdexamfetamine entries include ILimits = ST — confirm prior step therapy trials when submitting PA.
    • If a member has trialed the required alternative, include that documentation with the PA request.
    Step Therapy

    Document required prior trial (e.g., 'Must try ibuprofen') for ACTEMRA SOLN 200

    One ACTEMRA SOLN 200 entry explicitly states 'Must try ibuprofen', indicating a step therapy requirement; providers must document trial of the required agent before coverage will be approved for that ACTEMRA presentation.

    • ACTEMRA SOLN 200 entry: 'Must try ibuprofen' is specified — include evidence of ibuprofen trial in PA documentation.
    • If clinical contraindication to the required step exists, document rationale in the PA request.
    Note

    Consider tier assignments — higher tiers often imply PA/ST and specialty routing

    Formulary tier assignments (e.g., Tier 1A, 1B, 2, 3, 4) indicate coverage placement and may imply required step edits or higher cost sharing. Providers should consider tier when prescribing and follow any PA/ST flags associated with higher tiers.

    • Tier 4/specialty items often require PA and may need specialty pharmacy fulfillment.
    • Lower tiers (1A/1B) are preferred; when higher‑tier agents are requested, check for PA or ST requirements.
    Note

    No explicit step sequences in extract — document rationale if seeking exception

    This extract shows tier and administrative flags but does not define explicit step‑therapy sequences or required prior failures; when ST is indicated, follow the product‑level note or submit PA with clinical justification if step cannot be met.

    • Where ST is flagged but no sequence is detailed, include clinical rationale in PA to support exception.
    • Contact the plan for specific step‑therapy sequences not specified in the formulary extract.
    Note

    Tiering can imply step therapy; include prior therapy evidence when requesting higher‑tier drugs

    Tier assignments in the formulary may imply step therapy pathways (e.g., preferred drugs in tiers 1A/1B before higher‑tier alternatives). If a prescriber requests a higher‑tier agent, include evidence of prior therapy with preferred alternatives or submit PA explaining the clinical need.

    • Use tiering as a guide — check product row for ST/PA flags and include prior treatment history when requesting PA.
    • If step therapy is being bypassed, provide clinical justification in the PA submission.
    Documentation Required

    Follow D+/D indicators and PA/QL on insulin and antidiabetic entries

    Some insulin and antidiabetic entries include 'D+' or 'D' style indicators and PA/QL flags which suggest step edits or dispensing restrictions; providers should follow those indicators and submit PA/documentation when the formulary requires it.

    • Examples include HUMULIN R U‑500 and multiple GLP‑1/insulin products that list QL and PA.
    • If dispensing exceeds QL or deviates from 'D+' logic, include supporting documentation or request PA.
    Step Therapy

    Follow ST flags on combination products (document prior therapies or request PA)

    Some combination products and specific drugs show ST flags (e.g., EDARBI ILimits = QL(1 EA daily); amlodipine‑olmesartan entries marked ST). Providers must follow the ST requirement or document justification in a PA.

    • EDARBI shows ILimits = QL(1 EA daily); ST — document prior therapy if required.
    • Amlodipine‑olmesartan entries are marked ST — include trial of preferred alternative or PA justification.
    Documentation Required

    Check PA/ST on antihypertensives and provide prior trial documentation when required

    Some antihypertensive entries include PA or tiering that may reflect step edits; when prescribing these agents check the formulary line for ILimits = PA or ST and include prior therapy documentation if required for coverage.

    • Examples: select antihypertensive combinations list ILimits = PA or ST — submit PA with prior trial history or medical rationale.
    • Check QL values and D+/D indicators that may affect pharmacy adjudication.
    Step Therapy

    Adhere to step therapy for products labeled 'ST' or provide justification in PA

    A number of products are explicitly marked 'ST' or carry ST‑style indicators (e.g., apomorphine hydrochloride SOCT); providers must adhere to step therapy rules where present or include clinical justification when requesting PA.

    • Apomorphine hydrochloride SOCT lists ILimits = PA and QL and marks ST — obtain PA and document prior steps.
    • If step therapy cannot be met for clinical reasons, include that information with the PA.
    Step Therapy

    Document trials or exceptions when ST is required

    When a product row includes 'ST', providers must follow step therapy requirements prior to coverage; if step therapy is bypassed, provide clinical justification and supporting documentation with the PA to prevent denial.

    • Some products labeled ST require documented trial of lower‑tier alternatives before coverage.
    • Include dates, agents, durations, and clinical response in PA documentation when seeking exception.
    Billing Rule

    Comply with combined SP/PA or D+ notations on product lines

    Some formulary entries combine SP; PA or 'D+' notations indicating specialty dispensing plus prior authorization or dispensing restrictions; providers must comply with both specialty routing and PA requirements to ensure coverage.

    • Where SP; PA appears (e.g., select oncology or pulmonary agents), coordinate specialty pharmacy fulfillment and submit PA.
    • 'D+' indicators may require specific dispensing logic at the pharmacy; confirm with plan/pharmacy.
    Documentation Required

    Document age limits and ST for topical dermatologic products

    Several topical and dermatologic product rows include ST flags and age limits (AL); providers must document age eligibility and any required step therapy when requesting PA or filling prescriptions for these agents.

    • Benzoyl peroxide and clindamycin topical entries list AL(At least 12 yrs old) and ST — confirm member age and prior therapy evidence.
    • Isotretinoin entries require PA and have AL and QL requirements; include these in PA documentation.
    Step Therapy

    Follow ST on topical corticosteroids or provide PA justification

    Some topical corticosteroid and related products carry 'ST' indicators — providers must follow the step requirement or supply PA justification to avoid coverage denial at claim adjudication.

    • Entries like alclometasone and other corticosteroid topicals include ST and QL — include prior therapy details when requesting PA.
    • Pharmacies will enforce QL and max‑fill intervals noted on product lines.
    Prior Authorization

    Obtain PA for bisphosphonate/bone agents and follow SP where shown

    Bisphosphonate/bone density products may be tiered and have PA or specialty requirements (e.g., FOSAMAX PLUS D lists ILimits = PA); providers must request PA and follow specialty routing where required.

    • FOSAMAX PLUS D ILimits = QL(0.143 EA daily); PA — include clinical rationale and prior fracture/therapy history as applicable.
    • PROLIA and pamidronate entries show SP; PA or max‑fill per 180 days — coordinate specialty pharmacy and PA submission.
    Documentation Required

    When steps are implied by tiering, include prior therapy evidence with PA

    Tier assignments can imply step edits but explicit step sequences are not provided in this extract; when seeking coverage for higher‑tier drugs include documentation of prior therapies and clinical rationale in the PA request.

    • If formulary does not list explicit step sequence, use prior therapy history and clinical justification to support PA.
    • Contact plan for full step‑therapy rules if needed.
    Documentation Required

    Complete PA form and note plan response times for urgent/non‑urgent requests

    Providers must complete the Ambetter Prior Authorization form and submit all required information; urgent requests will be responded to within 24 hours and non‑urgent requests within 72 hours (unless state law requires faster response).

    • Use the Ambetter PA form and include all requested clinical information.
    • Expect 24‑hour turnaround for urgent PA requests and 72 hours for non‑urgent.
    Documentation Required

    Document package and 180‑day max‑fill limits (e.g., adalimumab) in PA requests

    Some products have package or max‑fill limits per specified windows (e.g., many adalimumab presentations show package(s) per 180 day(s) and 1 max fill(s) per 180 day(s)). Providers should confirm and document intended packaging/fill frequency in PA submissions.

    • Adalimumab entries show package limits per 180 days and 1 max fill per 180 days — include intended dispensing schedule in PA.
    • Where max‑fill per period applies, document clinical need for exceptions when requesting PA.
    Documentation Required

    Document and justify continuation beyond 7‑day new‑start opioid limits

    New starts for many injectable and oral opioid formulations are limited to a 7‑day supply; providers must document justification and request PA to continue therapy beyond the new‑start limit.

    • New‑start limit of 7 days applies to many opioid formulations — provide documentation of acute vs chronic need when requesting continuation.
    • If ongoing therapy is required, submit PA with clinical rationale for supply beyond 7 days.
    Billing Rule

    Adhere to QL values on product rows or request PA when exceeding limits

    Many formulary entries include explicit quantity limits (QL) — providers and dispensing pharmacies must adhere to these QLs or submit PA/documentation to exceed them.

    • Examples include QL(2 GM daily) for nitroglycerin (intra‑anal), QL(4 EA daily) for alprazolam strengths, and QL(900 ML per 30) for rivaroxaban suspension.
    • If a prescription exceeds QL, submit PA and supporting documentation to request an override.
    Documentation Required

    Record/adhere to QLs (e.g., XARELTO, enoxaparin) — exceptions require documentation

    Pharmacies and prescribers should record adherence to quantity limits: QL notations (e.g., XARELTO SUSR QL 900 mL per 30 days; enoxaparin SOLN QL(6 mL daily)) will be enforced and may require documentation for exceptions.

    • XARELTO suspension QL(900 ML per 30 day(s)) and enoxaparin SOLN QL(6 ML daily) are enforced at point of sale.
    • When requesting exceptions, include dosing regimen and clinical justification in PA.
    Prior Authorization

    Include PA documentation for GLP‑1 and specialty insulin products marked PA/QL

    Selected GLP‑1/insulin and other specialty antidiabetic products list PA alongside QL; providers must include PA documentation to support medical necessity when prescribing these agents.

    • OZEMPIC, TRULICITY and certain insulin presentations show QL and PA flags — include prior therapy and indication in PA submissions.
    • Claims for these agents may be denied without an approved PA.
    Documentation Required

    Observe QLs on antifungals and related agents or submit PA for exceptions

    Additional products across classes include QL notations (examples: antifungals, antifungal suspensions); providers must ensure prescriptions conform to the stated QL or submit PA with clinical justification.

    • Itraconazole CAPS ILimits = QL(4 EA daily); CRESEMBA CAPS ILimits = PA.
    • If prescribing beyond QL, include rationale and prior treatments in PA request.
    Documentation Required

    Provide full medical‑necessity documentation for specialty antineoplastics and PA‑marked agents

    Prescribers should provide documentation supporting medical necessity for specialty antineoplastic antibodies and other PA‑marked specialty agents; include prior therapies, staging, biomarkers, and dosing in the PA submission.

    • Oncology biologics (e.g., TAGRISSO, VECTIBIX, MVASI, ZIRABEV) list PA and often SP; include relevant clinical details in PA.
    • Lack of detailed documentation may result in PA denial or request for additional information.
    Denial Risk

    Exceeding QLs may cause denials — submit PA with supporting documentation

    Quantity limit edits (QL(...)) are enforced and can cause claim denial or require overrides; when a prescription exceeds the QL, providers must submit PA and documentation to support the exception.

    • QL notations across the formulary will be enforced at claim adjudication.
    • Include dosing, clinical reason, and duration when requesting override via PA.
    Billing Rule

    Adhere to fill‑frequency and max‑fill restrictions or request PA for exceptions

    Follow quantity‑limit and fill‑frequency restrictions noted on product lines (e.g., per‑day, per‑fill, 1 max fill every 90/180 days); pharmacies will enforce these and PA may be required for additional supply.

    • Examples include 'Limit 1 fill every 90 days' and per‑180‑day package limits — include requested fill frequency with PA.
    • Ensure pharmacy claims align with QL and max‑fill intervals or obtain PA.
    Documentation Required

    Confirm age limits and include age in PA documentation for AL/PA‑listed products

    For many products, age limits (AL) are specified alongside PA (e.g., tacrolimus topical entries); providers must document member age and obtain PA when PA is indicated by the formulary.

    • Tacrolimus topical entries list AL(At least 2 yrs old) and PA — verify member age and include in PA documentation.
    • Topical acne entries include AL(At least 12 yrs old) plus PA for some products.
    Documentation Required

    Reference product‑level Tier and ILimits in PA/claims to ensure correct adjudication

    Formulary product lines specify Tier, ILimits and Drug Requirements/ILimits which must be honored during claims processing and authorizations; providers should reference the exact formulary row when submitting PA or answering pharmacy inquiries.

    • Ensure PA submissions reference the formulary product row and its ILimits (PA, QL, ST, AL) to expedite review.
    • Pharmacies will adjudicate claims against the Tier/ILimits values; missing PA may result in denial.
    Denial Risk

    Denial notices will state specific reasons or missing information — respond promptly

    If a prior authorization request is disapproved, the plan's denial notice will include the specific reasons for denial or identify missing information necessary to complete the request; providers should review the notice and submit any requested information promptly.

    • Denial notices will give clear reasons for disapproval or list missing material information.
    • Respond to denial notices with the requested documentation or an appeal as appropriate.
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Initial Prescribing Limits and New-Start Rules

    Initial therapy limits

    Covered when ALL of the following initial therapy conditions are met:

    Initial supply limits: Many opioid and certain other products are limited for new starts to a 7‑day supply; initial dispensing must not exceed the 7‑day new‑start limit unless authorized.7‑day initial supply

    Documentation or PA is required to continue therapy beyond the initial supply.

    Utilization management flags

    Utilization management flags affecting initial coverage:

    ST/PA flags: Entries marked 'ST' indicate step therapy must be followed; entries marked 'PA' require prior authorization before coverage is approved.per product

    Specific step sequences or PA clinical criteria are not provided in this extract; see product‑specific PA rules.

    Continuation Beyond Initial Supply

    Continuation beyond new-start

    Continuation of therapy beyond the initial new‑start supply is permitted when ALL of the following are met:

    Continuation requirements: Ongoing therapy beyond the 7‑day new‑start supply requires documentation and/or prior authorization as indicated by the product's PA flag and must comply with the product's QL limits.

    Specific continuation clinical criteria are not present in this extract; follow PA documentation guidance where PA is required.

    Step Therapy Indicators and Examples

    ProductFormulary note / step indicator
    Lisdexamfetamine dimesylate CAPS / CHEWQL(1 EA daily) or QL(...) as listed; ST indicated (step therapy flag present)
    ProductStep requirement (explicit)
    ACTEMRA SOLN 200Must try ibuprofen before coverage; ILimits show 'Must try ibuprofen' and ST noted
    Tier exampleImplication for step edits / note
    Tier = 1A / 1BLower formulary tiers suggesting preferred agents; may imply earlier step before higher tiers
    Tier = 3Higher (non‑preferred) tiering that may trigger step edits from preferred tiers
    Tier = 4Specialty tier — often subject to PA and may be last step in therapy sequence
    Formulary tiering exampleNotes (step sequencing not specified)
    Products assigned Tier = 1B, 2, 3, 4Tier assignments are listed per product; explicit step‑through sequences or required prior failures are not provided in the excerpt
    Insulin / antidiabetic entryStep-edit indicator
    Insulin lispro / lispro prot insulin productsILimits include 'D+' or 'D' notation (e.g., D+; QL values) consistent with step‑edit indicators
    GLYXAMBI / metformin combinationsShown with 'D+' indicators on some entries suggesting step/dispense flags
    Combination productST flag present
    Amlodipine besylate - olmesartan medoxomil (combination)ILimits = ST indicated for some combination antihypertensive products
    Amlodipine - valsartan - hydrochlorothiazide (combination)Listed with ILimits = ST for certain formulations
    Antihypertensive examplePA / step note
    Various antihypertensives (e.g., valsartan, irbesartan, aliskiren)Some entries list PA or D+ and QL which may reflect step edits or prior therapy requirements before higher‑tier coverage
    Examples of agents with ST markerFormulary note
    Apomorphine hydrochloride SOCTILimits = PA; entry includes ST or ST‑style markers indicating step therapy may apply
    EQUETRO (olanzapine) formulationsListed ILimits include QL and ST flags (e.g., EQUETRO 100/300 mg with ST)
    Product labeled 'ST'Effect on coverage
    EQUETRO 100 MG / 300 MGILimits show QL and ST — step therapy is indicated before coverage of these formulations
    Multiple other products (various entries) with 'ST' flagProducts labeled ST require step therapy per formulary flags; specific prior fail‑throughs not described in excerpt
    D+ / SP flags exampleImplication (dispensing / specialty)
    Insulin and specialty agents with 'D+' notation'D+' or 'SP; PA' flags indicate additional dispensing or specialty requirements and may be associated with step edits
    Topical productStep therapy and age notes
    Benzoyl peroxide gels / liquidsEntries include AL (At least 12 yrs old) and ST/PA flags for some strengths/forms
    Clindamycin topical foam/gelILimits include AL and PA; some topical entries show ST marking alongside age limits
    Topical corticosteroid exampleStep therapy status
    Sulfamyelon / alclometasone / amcinonide topical corticosteroidsMultiple topical corticosteroid entries include ILimits = ST or QL; ST indicated though specific step sequence not listed
    Topical product (EUCRISA, others)Tiering / PA / QL
    EUCRISA (topical PDE4 inhibitor)Tier = 3; ILimits = QL(2 GM daily) and PA noted — product is tiered and may require PA
    Tacrolimus topical ointmentILimits include AL (At least 2 yrs old) and PA — tiering and PA flagged in formulary

    Quantity Limits (QL) — Examples and Product-Specific Values

    inv-170: Various stimulants and related agents — example QL formats
    Stimulant QL examplesQL(1 EA daily); QL(2 EA daily); QL(6 EA daily); QL(280 ML per 56 days)
    ST flag examplelisdexamfetamine dimesylate CAPS ILimits = QL(1 EA daily); ST (step therapy)
    Age limits with stimulantsAL(At least 6 yrs old) on many methylphenidate entries
    inv-171: ADALIMUMAB variants — package and 180-day limits
    Adalimumab family package/180‑day rulespackage(s) per 180 day(s) retail/mail; 1 max fill(s) per 180 day(s)
    Per‑day QL for injectionsQL(0.143 EA daily) shown on multiple pen/syringe presentations
    PA notedPA included on many adalimumab biosimilar entries
    inv-172: ACTEMRA ACTPEN SOAJ QL
    ACTEMRA ACTPEN QL (retail/mail)QL(3.6 mL per 28 day(s) retail; 4 mL per 28 day(s) mail)
    ACTEMRA tier/flagsACTEMRA ACTPEN listed Tier = 4; may include SP/PA on some lines
    DocumentationPA and QL must be honored for claims/authorization
    inv-173: OTEZLA TABS QL and package limits
    OTEZLA TABS QL and packageQL(2 EA daily); TBPK: 1 package(s) per 180 day(s) retail; PA
    Topical package examplesLimit Fill per 180 days appears on many topical GEL/SHAM/SOLN entries
    Age windowOTEZLA ILimits include AL(At least 45 yrs old Up to 79 yrs old)
    inv-174: multiple opioid products — QL examples across opioid products
    Opioid QL examplesQL(4 EA daily); QL(0.146 ML daily); QL(0.34 EA daily); QL(12 EA daily)
    New‑start restrictionNew starts limited to 7 day supply noted for many opioid formulations
    PA presenceSome opioid entries include PA; exceeding QL may require PA/documentation
    inv-175: Androgen/TESTOSTERONE products QL examples
    Testosterone/androgen QL examplesQL(1 EA daily); QL(9 EA per fill retail; 9 per fill mail); 1 max fill(s) per 75 day(s) retail
    PA and tier notesSome androgen presentations include PA or Tier 1B assignments
    Packaging limitsPer‑fill and per‑interval limits applied to injectables and patches
    inv-176: nitroglycerin (intra-anal) QL example
    Nitroglycerin (intra-anal) QLQL(2 GM daily)
    Formulary tierListed with Tier = 1B in topical/vasodilator grouping
    Claim requirementPharmacy claims must adhere to QL values listed
    inv-177: alprazolam tabs QL example
    Alprazolam tabs QLQL(4 EA daily)
    Strength variantsApplies to 0.25/0.5/1 mg and 2 mg tablet listings
    TieringEntries appear on Tier = 1A/1B depending on formulation
    inv-178: rivaroxaban SUSR QL example
    Rivaroxaban (susp) QLQL(900 ML per 30 day(s))
    Rivaroxaban tab QLQL(1 EA daily) for 10/20 mg; QL(2 EA daily) for 15 mg
    Starter pack noteStarter pack and SUSR forms have separate ILimits (e.g., 1 max fill per 365 for starter pack)
    inv-179: enoxaparin SOLN IJ QL example
    Enoxaparin SOLN IJ 300 MG/3ML QLQL(6 ML daily)
    Enoxaparin SOSY 60 MG/0.6MLILimits notation shows '30 Day(s)| Idaily;' and PA on some presentations
    Enoxaparin SOSY 30 MGQL(0.6 ML daily); some entries flagged SP; PA
    inv-180: budesonide inhalation QL example
    Budesonide inhalation (SUSP) QLQL(4 ML daily)
    Fluticasone inhalation examplesFluticasone propionate inhalation entries show C; QL(0.8 GM) or QL(4 ML daily) depending on formulation
    Claim adherenceQL must be enforced at claims/adjudication
    inv-181: XARELTO SUSR QL example
    XARELTO SUSR QL (duplicate)QL(900 ML per 30 day(s))
    Associated tab limitsXARELTO TABS 10/20 MG QL(1 EA daily); 15 MG QL(2 EA daily)
    Specialty flagSome rivaroxaban lines include SP/PA annotations
    inv-182: XARELTO TABS 10/20 MG QL example
    XARELTO TABS (10/20 MG) QLQL(1 EA daily)
    Alternate strengthXARELTO TABS 15 MG QL(2 EA daily)
    Starter packXARELTO STARTER PACK ILimits noted (max fills per 365 days)
    inv-183: XARELTO TABS 15 MG QL example
    XARELTO 15 mg QLQL(2 EA daily)
    Tab tieringListed Tier = 2 or 1B depending on presentation
    Related susp QLSUSR form QL(900 ML per 30 day(s))
    inv-184: enoxaparin IJ 300 MG/3ML QL example (duplicate reference)
    enoxaparin IJ 300 MG/3ML QL (duplicate)QL(6 ML daily)
    Use noteApplied to injectable/IV presentations; PA may apply for some strengths
    Claims noteQL must be honored on retail/mail claims
    inv-185: enoxaparin SOSY 30 MG QL example
    enoxaparin SOSY 30 MG QLQL(0.6 ML daily)
    Specialty/PASome SOSY presentations flagged SP; PA
    Related SOLN QLSOLN IJ 300 MG/3ML QL(6 ML daily)
    inv-186: perampanel TABS 6 MG QL example
    Perampanel 6 mg QLQL(2 EA daily)
    PA flagPA indicated on perampanel 6 mg listing
    Class noteListed under Anticonvulsants with additional QL variants for other strengths
    inv-187: clobazam SUSP QL example
    Clobazam suspension QLQL(16 ML daily)
    Tablet variantsClobazam tabs show lower per‑day EA QL (e.g., 2–12 EA daily depending on presentation)
    PA/flagsSome clobazam entries include PA
    inv-188: rufinamide TABS 400 MG QL example
    Rufinamide 400 mg tabs QLQL(8 EA daily)
    Other strengthsRufinamide 200 mg QL(2 EA daily)
    PA flagPA present on some rufinamide entries
    inv-189: SPRAVATO (84 MG) QL example
    SPRAVATO 84 mg QLQL(TEA daily) (notation appears in formulary)
    PA requirementILimits = PA for both 56 mg and 84 mg doses
    TieringSPRAVATO listed Tier = 3 for doses shown
    inv-190: naloxone hcl LIQD QL limits example
    Naloxone liquid QL limits2 EA per retail; 2 max fill(s) per 30 days retail
    OTC/RX noteNaloxone lines may include RXIOTC annotation (OTC/Rx status) and tiering
    Claim enforcementMax fills per 30 days enforced at retail claims
    inv-191: ondansetron tabs QL example
    Ondansetron 4 mg tabs QLQL(60 EA per fill retail; 60 per fill mail)
    Alternative presentationsSolutions and IV forms have separate QL (e.g., QL(3.34 ML) for some SOLN entries)
    PA/tiersSome ondansetron SOLN/IV lines include PA
    inv-192: HUMULIN R U-500 QL example
    HUMULIN R U-500 QLQL(1.34 ML daily)
    Tiering and D+/D indicatorsInsulin entries include D+/D indicators and tier placements affecting step edits
    Claims noteQL applied per day for concentrated insulin products
    inv-193: GLYXAMBI/metformin combo QL examples
    GLYXAMBI/metformin combo QL examplesQL(1 EA daily) and QL(3 EA daily) variants shown depending on product
    D+ indicatorSome GLP‑1/combination entries include D+ or PA flags
    TieringGLYXAMBI listed Tier = 2 with QL noted
    inv-194: griseofulvin microsize SUSP QL example
    Griseofulvin microsize suspension QLQL(1 EA daily)
    Age limitAL(At least 2 yrs old) noted on suspension formulation
    Formulation variantsTablets and ultramicrosize forms have different QL annotations
    inv-195: itraconazole CAPS QL example
    Itraconazole capsules QLQL(4 EA daily)
    Itraconazole solution QLQL(20 ML) and QL(6 EA daily) variants for SOLN presentations
    PA flagPA appears on some itraconazole and related antifungal entries
    inv-196: itraconazole SOLN QL examples
    Itraconazole solution QL examplesQL(20 ML); QL(6 EA daily) (multiple SOLN limits shown)
    Capsule vs solutionCaps and SOLN have distinct QL formats in the formulary
    PA notePA present for some antifungal entries (e.g., CRESEMBA)
    inv-197: voriconazole TABS QL example
    Voriconazole tabs QLQL(A4 EA daily) as listed
    PA/tieringVoriconazole lines show Tier = 1B and may include PA
    Related antifungalsFormulary lists multiple azole agents with varied QL formats
    inv-198: diphenhydramine LIQD QL examples
    Diphenhydramine liquid QL examplesQL(20 ML daily) and QL(6 EA daily) variants
    Capsule/tablet variantsDiphenhydramine CAPS/TABS entries show different QL (e.g., QL(4 EA daily))
    TieringAntihistamine entries appear on Tier 1A/1B depending on form
    inv-199: cetirizine tabs QL example
    Cetirizine tabs QLQL(6 EA daily)
    TieringCetirizine listed Tier = 1A with QL annotations
    Formulation noteOther antihistamine forms have separate QL values
    inv-200: cholestyramine POWD QL example
    Cholestyramine powder QLQL(25.2 GM daily)
    Pack vs powderPack formulations have separate QL entries (e.g., QL(6 EA daily) for PACK variants)
    TieringListed Tier = 1B for powder
    inv-201: colesevelam PACK QL example
    Colesevelam pack QLQL(1 EA daily)
    PA flagColesevelam PACK lists PA on some presentations
    Alternate QLColesevelam tablets may show QL(7 EA daily) for other forms

    Additional Quantity Limits and Examples

    inv-202: colestipol GRAN QL example
    Colestipol GRAN QLQL(6 GM daily)
    Pack/tablet variantsColestipol PACK/TABS have separate QL annotations
    TieringColestipol listed Tier = 1B/4 depending on presentation
    inv-203: gemfibrozil TABS QL example
    Gemfibrozil tablet QLQL(2 EA daily) or QL(3 EA daily) variants
    TieringGemfibrozil appears on Tier = 1B in several listings
    Related fibratesFenofibrate entries show D+ indicators and other QL formats
    inv-204: lovastatin tabs QL examples
    Lovastatin tabs QL examplesQL(TEA daily) or QL(2 EA daily) variants depending on strength
    TieringLovastatin listed Tier = 1A/1B with D+ indicators on some strengths
    Claim noteDifferent strengths/forms may have distinct QL enforcement
    inv-205: clonidine hcl tabs QL example
    Clonidine tablets QLQL(8 EA daily) (variants QL(2 EA daily) also appear)
    TieringClonidine entries appear on Tier = 1A/1B depending on form
    Formulation notePatches and ER forms may have alternate ILimits
    inv-206: prazosin caps QL example
    Prazosin capsules QLQL(4 EA daily)
    TieringPrazosin listed Tier = 1B in antihypertensive grouping
    Related combosSome antihypertensive combos include QL(1 EA daily) and ST flags
    inv-207: trandolapril-verapamil QL example
    Trandolapril‑verapamil QLQL(1 EA daily)
    TieringListed Tier = 3 for certain strength combinations
    Usage noteAppears among antihypertensive combinations with QL enforcement
    inv-208: trandolapril-verapamil duplicate QL reference
    Trandolapril‑verapamil (duplicate) QLQL(1 EA daily)
    Reference duplicationSame ILimits repeated across multiple strength rows
    Claims noteEnforce per‑entry QL at adjudication
    inv-209: LENVIMA QL example
    LENVIMA QL exampleQL(2 EA daily) (20 mg daily dose); lower QL(1 EA daily) for other doses
    PA/SPPA noted; some doses include SP designation
    Dose-dependent QLQL varies by daily dose as listed
    inv-210: XIFAXAN 200 mg QL example
    XIFAXAN 200 mg retail QLQL(3 EA daily; 9 EA per 3 day(s) retail)
    Age/PA noteILimits include AL(At least 12 yrs old) and PA in some cases
    Course formattingRetail vs short‑course (3‑day) QL explicitly shown
    inv-211: minoxidil QL example
    Minoxidil QL exampleQL(4 EA daily)
    Strengths listed2.5 mg and 10 mg tablet entries shown with QL formats
    TieringMinoxidil entries appear on Tier = 1B in this extract
    inv-212: TAGRISSO QL example
    TAGRISSO 40 mg QLQL(2 EA daily)
    PA and SPPA noted; some oncology agents include SP designation
    Higher dose noteTAGRISSO 80 mg listed with ILimits = PA
    inv-213: GILOTRIF QL example
    GILOTRIF QLQL(1 EA daily)
    SP/PA flagsGILOTRIF entries may include SP; PA annotations
    Oncology contextListed among antineoplastic agents with QL/PA enforcement
    inv-214: paclitaxel 100 MG/16.7ML — SP; PA noted
    Paclitaxel 100 mg/16.7 mL — utilization notesSP; PA (QL not clearly numeric in this segment)
    Site-of-careSpecialty pharmacy (SP) and prior authorization typically required
    Claims handlingProvider must submit PA and site‑of‑care documentation for coverage
    inv-215: multiple listed products QL examples
    Sample multi‑product QL examplesQL(2 EA daily); QL(0.072 EA); QL(30 ML daily); Limit 1 fill every 90 days
    ContextsExamples span psychiatric, antiviral, and other therapeutic classes
    EnforcementQL and interval limits are enforced at claims/adjudication
    inv-216: HEMANGEOL SOLN QL example
    HEMANGEOL solution QLQL(75 ML daily)
    Topical corticosteroid examplesFluticasone propionate OINT QL(15.15 GM daily); hydrocortisone butyrate OINT QL(12.9 GM daily)
    Formulation noteQL varies by formulation (ointment/cream/lotions) and is listed per entry
    inv-217: metoprolol succinate TB24 QL example
    Metoprolol succinate TB24 200 mg QLQL(2 EA daily)
    D+ indicatorSome metoprolol strengths include D+ or other step/edit markers
    TieringListed Tier = 1B for extended‑release 200 mg
    inv-218: digoxin SOLN QL example
    Digoxin solution QLQL(2 EA daily)
    Formulation-specificApplies to DIGOXIN SOLN PO 0.05 MG/ML listing
    PA flagSome digoxin lines include SP; PA annotations
    inv-219: sildenafil citrate (PH) SOLN QL example
    Sildenafil (PH) solution QLQL(37.5 ML daily)
    SP/PAListed with SP; PA in pulmonary hypertension context
    Formulation noteSolution form QL differs from tablet QL entries

    Remaining Quantity Limit Examples

    inv-220: nifedipine CAPS QL example
    Nifedipine 20 mg caps QLQL(9 EA daily)
    TB24/ER variantsExtended‑release TB24 forms show different ILimits and D+ markers
    TieringNifedipine entries appear on Tier = 1B
    inv-221: TWIRLA transdermal QL example
    TWIRLA transdermal QLQL(3 EA per 28 day(s) retail; 9 EA per 84 days)
    Transdermal pack notePer‑28‑day and per‑84‑day QL shown for patch systems
    Formulary placementListed among contraceptive entries with tier annotations
    inv-222: isotretinoin QL example
    Isotretinoin QLQL(60 GM per 30 day(s) retail; 60 GM per 30 days mail)
    PA requirementIsotretinoin entries include PA
    Age/usage noteAge limits and monitoring implied though not detailed in extract
    inv-223: ciclopirox cream QL example
    Ciclopirox cream QLQL(90 GM per 1 max fill(s) per 30)
    Ciclopirox GEL/SHAM/SOLN limitsQL(.35 GM daily); QL(10 ML daily); Limit Fill per 180 days with 1 max fill(s) per 180 days retail
    Topical fill‑intervalsMany topical agents include 'Limit Fill per 180 days' annotations
    inv-224: clotrimazole cream QL and fill limits
    Clotrimazole cream QL and fill limitsQL(4.5 GM daily); Limit Fill per 180 days; 1 max fill(s) per 180 day(s) retail
    Solution/pack QLClotrimazole SOLN QL(10 ML); SOLN entries may have 180‑day fill limits
    RXIOTCSome topical entries include RXIOTC designation (OTC/Rx) in listing
    inv-225: ciclopirox GEL/SHAM/SOLN QL examples
    Ciclopirox GEL/SHAM/SOLN QL examplesQL(90 GM per 1 max fill(s) per 30); QL(.35 GM daily); QL(10 ML daily)
    Fill intervalLimit Fill per 180 days with 1 max fill(s) per 180 day(s) retail for certain formulations
    Product variabilityQL values vary by formulation (cream/gel/sham/soln)
    inv-226: fluticasone propionate formulations QL examples
    Fluticasone propionate QL examplesQL(6 ML daily); QL(6 GM daily); QL(15.15 GM daily); QL(4 GM daily) depending on formulation
    Hydrocortisone butyrate QLQL(3 GM daily); QL(12.9 GM daily); QL(5 ML daily)
    Formulation noteOintment/lotions/solutions have distinct QL entries per product row
    inv-227: hydrocortisone butyrate formulations QL examples
    Hydrocortisone butyrate formulations QLQL(3 GM daily); QL(12.9 GM daily); QL(5 ML daily)
    RXIOTC noteSome hydrocortisone entries include RXIOTC annotations
    Age/fill limitsTopical corticosteroids may include age limits and fill‑interval restrictions
    inv-228: imiquimod 5% QL example
    Imiquimod 5% QLQL(12 EA per fill retail; 12 per fill mail)
    PA/age notesSome immunomodulator/topical entries include AL and PA annotations
    Fill unitQL expressed per fill for single‑use applicator kits/each counts
    inv-229: lidocaine hcl SOLN QL example
    Lidocaine solution QLQL(10 ML)
    Patch/PRSY variantsLidocaine patch 5% may be PA; lidocaine PRSY entries note 365‑day max fills
    Formulation enforcementDifferent topical forms enforce distinct QL/interval rules
    inv-230: PROLIA max fill per 180 days
    PROLIA max fill per 180 daysmax fill(s) per 180 day(s)
    PROLIA specialty flagPROLIA listed Tier = 4; ILimits include max‑fill per 180 days and PA/SP as indicated
    Claims handlingPA and specialty dispensing must be honored for PROLIA claims
    inv-231: desmopressin tabs QL example
    Desmopressin tabs QLQL(6 EA daily)
    Solution/other formsDesmopressin SOLN IJ and sprays have separate ILimits (e.g., QL(0.572 EA daily) for some SOLN)
    PA flagDesmopressin entries include PA on some formulations
    inv-232: tolvaptan tabs QL example
    Tolvaptan tabs QLQL(2 EA daily)
    PA/SPTolvaptan lines indicate PA and in some cases SP; PA
    TieringListed Tier = 3 for tolvaptan in this extract
    inv-233: lubiprostone QL example
    Lubiprostone QLQL(2 EA daily)
    QL variantSome entries show QL(0.072 ML daily) for solution presentations
    TieringListed Tier = 1B for oral lubiprostone
    inv-234: PYZCHIVA QL example
    PYZCHIVA QLQL(3.47 ML)
    Formulation notePresented as ML quantity for injectable/solution presentations
    TieringListed Tier = 1B for PYZCHIVA in extract
    inv-235: SKYRIZI SOLN QL example
    SKYRIZI solution QLQL(0.36 ML)
    PA/SPSKYRIZI listings include PA and SP annotations in adjacent entries
    Dose formattingQL expressed in mL for injectable biologic solutions

    Specialty Pharmacy and Dispensing Requirements

    Note
    Note

    Biosimilar Listings and Handling

    Note
    Note
    Note

    Formulary Terms and Abbreviations

    inv-120: Generic drugs definition — generic as first-line when available
    Generic drugs definitionGeneric drugs are medicines with the same active ingredients as brand‑name counterparts and are considered first‑line when available.
    Specialty vs non‑specialtyPreferred brand drugs are listed on Tier 2 when generics are not suitable
    Formulary scopeFormulary lists covered drugs subject to tier, QL, AL, PA, ST as indicated
    inv-121: Specialty drugs definition — specialty tier explanation
    Specialty drugs definitionSpecialty drugs are used for complex chronic conditions that may require special handling, storage, or clinical management and may require fulfillment at participating specialty or hemophilia network pharmacies.
    Specialty tier impactSpecialty‑tier drugs often require PA and may be dispensed via SP (specialty pharmacy)
    ExamplesMultiple oncology and biologic agents (e.g., MVASI, ZIRABEV, TAGRISSO) are flagged SP/PA in the formulary
    inv-122: QL definition (example formats)
    QL notation definitionQL(...) denotes a Quantity Limit expressed per period or unit (examples: QL(0.143 EA daily); QL(900 ML per 30 day(s)); QL(2 EA daily)).
    Formats observedPer‑day (EA daily), per‑fill (60 EA per fill), per‑X‑days (9 EA per 3 day(s)), per volume (ML/GM) formats used
    EnforcementQL edits are enforced at claims and may require PA/documentation when exceeded
    inv-123: PA definition — prior authorization required
    PA definitionPA indicates Prior Authorization is required for coverage — providers must submit a PA form and supporting information.
    Where PA appearsPA appears on many specialty/biosimilar and selected high‑cost agents (e.g., adalimumab variants, OTEZLA, oncology biologics)
    Denial riskClaims without required PA may be denied; denial notices will identify missing information or reason for denial
    inv-124: New starts limited to 7 day supply — definition/usage
    New‑start 7‑day supply policyNew starts limited to 7 day supply — initial prescriptions for many injectable/oral opioid formulations limited to 7 days unless additional authorization provided.
    Continuation guidanceProviders should document medical necessity for ongoing therapy beyond initial 7‑day supply; PA may be required
    ScopeApplies to many opioid and select injectable products in the formulary
    inv-125: QL definition — maximum quantity permitted examples
    QL general definitionQL denotes the maximum quantity permitted over the stated time period for the specified product (formats include per day, per fill, per X days, volume or weight units).
    Example formatsQL(2 GM daily); QL(4 EA daily); QL(900 ML per 30); QL(60 EA per fill)
    Claims implicationPrescriptions exceeding QL may require PA or additional documentation
    inv-126: PA definition — administrative requirement indicated for coverage
    PA administrative definitionPA (Prior Authorization) is an administrative requirement indicating the product may require approval from the plan before coverage is granted.
    Provider actionProviders must submit required documentation and PA form; urgent requests handled per response time guidance
    Common PA usesCommon for specialty biologics, oncology agents, certain topical/antifungal agents, and digestive enzyme non‑FDA uses
    inv-127: QL definition — general duplicate
    QL general format (repeat)Quantity Limit — maximum permitted quantity specified over a time period (example: QL(900 ML per 30 day(s))).
    Unit examplesEA (each), ML (milliliter), GM (gram), package(s)
    Enforcement noteFormulary ILimits entries are enforced during claims processing and may trigger PA if exceeded
    inv-128: PA — prior authorization (placeholder duplicate)
    PA (utilization management) definition duplicatePrior Authorization — utilization management requirement indicated for certain products; lack of PA may trigger denial.
    Where shownPA shown adjacent to product rows as ILimits = PA or SP; PA
    Provider responsibilitySubmit PA and supporting documentation when PA flag present
    inv-129: QL examples — per-day/per-fill formats
    Per‑day / per‑fill QL examplesFormats include QL(1 EA daily), QL(60 EA per fill), QL(900 ML per 30)
    Volume and count unitsExamples show EA, ML, GM units and per‑fill or per‑period caps
    InterpretationUse exact ILimits from formulary row when adjudicating claims
    inv-130: PA definition — prior authorization required example
    PA required examplePrior authorization is required for non‑formulary drugs and drugs noted with PA on the formulary; providers must submit PA form and necessary information.
    Response timesUrgent requests: 24 hours; Non‑urgent: 72 hours (unless state law requires faster)
    Denial notice contentDenial notices will include specific reasons or identify missing information required to complete request
    inv-131: QL definition (duplicate reference)
    Quantity Limit (QL) — conciseMaximum units allowed in a specified time period as noted in the formulary entry (e.g., QL(1 EA daily)).
    Common unitsEA, ML, GM, package(s), per fill
    Rule of applicationApply the exact QL string from the formulary row when processing claims or PA
    inv-132: PA / SP — specialty prior authorization definition
    PA / SP definitionPA / SP indicates Prior Authorization and Specialty Pharmacy requirement — utilization management steps required for coverage of specialty agents.
    ExamplesMany oncology and biologic agents (e.g., LENVIMA, MVASI, VITRAKVI) are marked SP; PA
    Provider actionProviders must route prescriptions to specialty network pharmacies where SP is required and obtain PA as indicated
    inv-133: PA definition (duplicate)
    PA definition (repeat)Prior Authorization — coverage requires approval before dispensing when ILimits = PA is shown.
    Denial riskClaims without required PA may be denied
    Common usagesSeen across specialty biologics, oncology agents, enzymes and selected high‑cost medications

    Background and Scope

    The formulary lists FDA‑approved brand and generic drugs covered under the prescription drug benefit and indicates a preference for generics where available. Generics are preferred when available; preferred brand drugs appear on Tier 2 when a generic is not suitable. The Formulary is a guide and not all dosage forms or strengths may be covered.

    Policy Revision History

    2026-01formulary_updateLatest

    Ambetter Formulary updated (document labeled 'Ambetter Formulary Updated January 2026') with tier assignments, PA and QL flags across multiple product classes including specialty oncology agents and biosimilars.

    2026-01-01policy_effective_date

    Policy effective date set to 2026-01-01 for this Ambetter formulary coverage criteria document (AMB25-AHS-C-00023-FL).

    2026-01utilization_management_update

    Added or affirmed utilization controls including quantity limits (QL), age limits (AL), prior authorization (PA) flags and new-start 7-day opioid supply limits referenced in the formulary extract.